drugset
Drugs / Allogeneic Mesenchymal Human Stem Cells
last change Aug 2025 re-read 3 minutes ago

Allogeneic Mesenchymal Human Stem Cells

Cell therapy

Developed for
diabetes mellitus · ischemic disease · type 2 diabetes mellitus
Investigated by
Joshua M Hare · National Heart, Lung, and Blood Institute (NHLBI)

Trials 2

today NCT04776239 · Ph 1/2 NCT02886884 · Ph 1/2
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04776239 Aug 2021 → Mar 2025 diabetes mellitus, ischemic disease Joshua M Hare Completed No outcome recorded
Phase 1/2 NCT02886884 Oct 2017 → Aug 2019 type 2 diabetes mellitus Joshua M Hare Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Allogeneic Mesenchymal Human Stem Cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT02886884 ↗
1

NCT04776239 ↗
Modality Cell therapy “Allogeneic Mesenchymal Human Stem Cells Infusion Therapy” NCT02886884 ↗
Route Intravenous “one peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells” NCT02886884 ↗